为了调查患有恶性卵巢生殖细胞肿瘤 (MOGCT) 的儿童、青少年和年轻人 (AYA) 的结局，我们分析了 2006 年至 2022 年间诊断患有 MOGCT 的 61 名年龄≤39 岁患者的数据。其中 59 名接受化疗的患者初步诊断后，57 人接受了 BEP（每周 30 单位的博莱霉素标准剂量，n = 13）或 bEP（第一天 15 单位/平方米的博莱霉素减量剂量，n = 44）。 5年总生存率（OS）和无事件生存率（EFS）分别为98.3%和84.9%。减少博来霉素剂量不会对生存产生不利影响。术后 3 个月内肿瘤标志物正常化与更好的 EFS 显着相关 (p < 0.01)。在 59 名幸存患者中，8 名经历了与手术相关的更年期，而 49 名则表现出月经恢复。化疗完成后，博莱霉素剂量对肺功能没有显着影响，也没有明显的肾毒性。大约 60% 和 25% 的幸存者在化疗结束时和 1 年后分别出现周围神经病变 (p < 0.01)。患有 MOGCT 的儿童和 AYA 具有良好的存活率和最小的长期毒性，并且不受博来霉素剂量减少的影响。肿瘤标志物的快速正常化与预后的改善相关。

To investigate the outcomes of children, adolescents, and young adults (AYAs) with malignant ovarian germ cell tumors (MOGCTs), we analyzed the data of 61 patients aged ≤39 years diagnosed with MOGCT between 2006 and 2022. Among 59 patients who received chemotherapy after initial diagnosis, 57 received BEP (standard dose of bleomycin with 30 units per week, n = 13) or bEP (reduced dose of bleomycin with 15 units/m2 on day 1, n = 44). The 5-year overall survival (OS) and event-free survival (EFS) rates were 98.3% and 84.9%, respectively. Reduced bleomycin dose did not adversely affect survival. Normalization of tumor markers within 3 months after surgery was significantly associated with better EFS (p < 0.01). Of the 59 surviving patients, 8 experienced surgery-related menopause, while 49 demonstrated menstrual recovery. After completion of chemotherapy, there was no significant difference in pulmonary function regarding bleomycin dose, and no overt nephrotoxicity. Approximately 60% and 25% of survivors experienced peripheral neuropathy at the end of chemotherapy and after 1 year, respectively (p < 0.01). Children and AYAs with MOGCT have favorable survival rates with minimal long-term toxicity, which are not influenced by a reduced bleomycin dose. Rapid normalization of tumor markers is associated with improved outcomes.